Long-acting antibodies for moderate to severe ulcerative colitis
Part of Digestive system clinical trials.
This study tests new long-acting antibodies, given alone or in combination, for people with moderate to severe ulcerative colitis. The goal is to see if these treatments can help reduce inflammation and improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with ulcerative colitis (UC) for at least 3 months, confirmed by a colonoscopy and biopsy.
- Your UC is currently active, with inflammation in a section of the colon at least 15 cm (about 6 inches) long.
- Your disease is moderate to severe, meaning you have a certain level of symptoms (a Mayo score of 5-9) and are having rectal bleeding and visible inflammation on colonoscopy.
- You have not been diagnosed with Crohn's disease or another type of inflammatory bowel disease that is not UC.
- You do not have severe complications like a bowel perforation, toxic megacolon, or a condition that would likely need surgery during the study period.
- You have not already tried and failed 4 or more different advanced therapies (approved or investigational) for UC.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing long-lasting antibodies given alone or in combinations to keep IBD under control over the long term. It's for people who already did well in the initial study and want to continue treatment.
This study tests an experimental drug called RO7837195 for people with moderate to severe ulcerative colitis (UC) who haven't gotten enough help from other treatments. It aims to see if this new drug can reduce inflammation and improve symptoms.
This study tests several new treatments to see if they are safe and helpful for people with moderate to severe ulcerative colitis. If you have not responded well to standard treatments, this might be an option.
This study tests a new medication called BI 3032950 for people with ulcerative colitis who have already tried other advanced treatments (biologics or targeted therapies) that didn't work well enough or caused problems. The goal is to see if the new drug is safe and helps control inflammation in the colon.
This trial tests a new treatment for people with ulcerative colitis (UC) whose disease is active despite taking only mesalamine or sulfasalazine. It aims to find a therapy that can reduce inflammation and improve symptoms.
This study tests a new combination of two drugs to see if they are safe and help reduce ulcerative colitis symptoms. It is for people who have not gotten enough relief from other treatments.
Hear when a new Ulcerative Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.